BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29989572)

  • 1. [Bispecific Antibodies: Formats and Areas of Application].
    Vasilenko EA; Mokhonov VV; Gorshkova EN; Astrakhantseva IV
    Mol Biol (Mosk); 2018; 52(3):380-393. PubMed ID: 29989572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy with bispecific antibodies: Clinical experience.
    Thakur A; Lum LG
    Curr Opin Mol Ther; 2010 Jun; 12(3):340-9. PubMed ID: 20521223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
    Acheampong DO
    Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated T cells armed with bispecific antibodies kill tumor targets.
    Bhutani D; Lum LG
    Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
    Thakur A; Lum LG
    Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to antibody therapy.
    Weiner LM; Adams GP
    Oncogene; 2000 Dec; 19(53):6144-51. PubMed ID: 11156528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.
    Kiefer JD; Neri D
    Immunol Rev; 2016 Mar; 270(1):178-92. PubMed ID: 26864112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double whammy: bispecific antibodies help immune cells attack tumors.
    Shekhar C
    Chem Biol; 2008 Sep; 15(9):877-8. PubMed ID: 18804023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.